Watching INTERPACE BIOSCIENCES, INC.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planINTERPACE BIOSCIENCES, INC.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Interpace Biosciences continues to recover from the April 2025 CMS decision to cease reimbursement for its PancraGEN pancreatic cancer test, which forced the company to stop accepting related specimens in May 2025. While the company achieved net income in Q2 2026 ($158K) versus a loss in Q2 2025, six-month revenue declined 12.5% year-over-year ($18.2M vs $20.7M) reflecting the lost PancraGEN revenue stream, and the company remains heavily dependent on its thyroid cancer tests (ThyGeNEXT/ThyraMIR). Aggressive cost-cutting in sales & marketing (down ~23-24%) helped restore profitability despite lower revenue, but cash reserves remain thin at $2.7M and share count ballooned over 6x (4.6M to 27.8M shares) due to preferred stock conversion, creating massive dilution risk.
Red Flags Detected (8)
Loss of CMS/Medicare reimbursement for PancraGEN test (April 2025) eliminated a core revenue stream, forcing cessation of specimen acceptance
H1 2026 revenue down 12.5% YoY ($18.16M vs $20.75M), driven by discontinuation of pancreatic cancer testing
Common stock delisted from Nasdaq per risk factor disclosures
5 more red flags detected
Key Takeaways
Company returned to profitability in Q2 2026 primarily through cost reduction rather than revenue growth
Loss of PancraGEN Medicare reimbursement remains the dominant overhang on the business
3 more takeaways
Filing Overview
What This Means
Quarterly Report: Interim filing with unaudited financial data for the quarter.